MedTrace Logo

Efficacy and Safety of HRS9531 Tablet in Obese Subjects

NCT06841445 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2026-04-03

No results posted yet for this study

Summary

To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.

Conditions

  • Chronic Management of Body Weight

Interventions

DRUG

HRS9531 Tablet

HRS9531 Tablet dose 1

DRUG

HRS9531 Tablet

HRS9531 Tablet dose 2

DRUG

HRS9531 Tablet

HRS9531 Tablet dose 3

DRUG

HRS9531 Tablet placebo

HRS9531 Tablet placebo

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2026-01-08
Completion
2026-01-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06841445 on ClinicalTrials.gov